E1 ReplicatedModerate confidencePEM not requiredRCTPeer-reviewedReviewed
Standard · 3 min
Levels of DHEA and DHEAS and responses to CRH stimulation and hydrocortisone treatment in chronic fatigue syndrome.
Cleare, A J, O'Keane, V, Miell, J P · Psychoneuroendocrinology · 2004 · DOI
Quick Summary
This study looked at stress hormone levels in people with ME/CFS, specifically a hormone called DHEA that affects mood, memory, and sleep. Researchers compared 16 ME/CFS patients to 16 healthy controls and tested how their bodies responded to a hormone challenge. They also gave some patients a low-dose steroid medication for a month to see if it helped. The findings suggest that DHEA levels are higher in ME/CFS and may relate to how disabled patients feel, and that low-dose steroid treatment can lower these levels and improve symptoms in some patients.
Why It Matters
Understanding hormone abnormalities in ME/CFS is crucial because the condition involves dysregulation of the stress-response system; this study provides evidence that normalizing DHEA levels through low-dose hydrocortisone may reduce fatigue in responsive patients. These findings support further investigation of steroid therapy as a targeted biomarker-informed treatment approach for ME/CFS.
Observed Findings
Basal DHEA levels were significantly higher in CFS patients than controls (14.1 ± 2.2 ng/ml vs. 9.0 ± 0.90 ng/ml, P=0.04).
Higher basal DHEA levels correlated with higher self-reported disability scores in the patient group.
After 1 month of hydrocortisone treatment, both DHEA and DHEA-S levels were significantly reduced in patients (DHEA: 8.9 ± 0.97 ng/ml, P=0.015; DHEA-S: 233.4 ± 41.6 μg/dl, P=0.03).
Patients who showed clinical improvement in fatigue after hydrocortisone demonstrated a significant increase in DHEA responsiveness to CRH stimulation (P=0.029).
Inferred Conclusions
CFS is associated with a state of relative DHEA excess (rather than deficiency), and this elevation correlates with symptom severity.
Low-dose hydrocortisone therapy normalizes DHEA levels and enhances the adrenal gland's capacity to respond to the stress hormone CRH, particularly in patients who experience clinical benefit.
DHEA responsiveness to CRH stimulation may serve as a biomarker of treatment response to hydrocortisone in ME/CFS.
Remaining Questions
Does the elevated DHEA reflect primary adrenal overproduction or altered metabolism, and what is the underlying mechanism?
How do these findings apply to the broader ME/CFS population, and are there predictors of who will respond clinically to hydrocortisone therapy?
What This Study Does Not Prove
This study does not prove that elevated DHEA *causes* ME/CFS or disability; it only shows a correlation. The small sample size (n=16 per group) limits generalizability, and the lack of a standardized ME/CFS case definition (e.g., no explicit post-exertional malaise criteria) means the patient cohort may not be fully representative of the broader ME/CFS population. The modest sample size also means the trend toward increased DHEA responsiveness after hydrocortisone (P=0.053) did not reach statistical significance in the full group.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.